Developing inhaled therapeutics for respiratory diseases, specifically targeting severe asthma patients.
LATEST ROUND
Series B
$103M · 2026-01-10
RAISED ON RECORD · USD
$103M
across 1 verified round
INVESTORS
11
2 leads
SOURCES
2
from 2 publishers
Developing inhaled therapeutics for respiratory diseases, specifically targeting severe asthma patients.
2 sources
Sources agree on the Series B, $103 million amount, January 10, 2026 announcement date, and investor syndicate. The Boston dateline does not establish headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $103M | 2026-01-10 | Forge Life Science Partners, RA Capital Management | No recent discussion |
2 sources [ VERIFIED ] read against 2 sources Sources agree on the Series B, $103 million amount, January 10, 2026 announcement date, and investor syndicate. The Boston dateline does not establish headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: kinasettherapeutics.com, businesswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage | ||||